An Observational, Retrospective, Postmarketing Safety Study of Trivalent Cell Culture Seasonal Influenza Vaccination (TIVc) (Optaflu) among Adults in Routine UK Care

Trial Profile

An Observational, Retrospective, Postmarketing Safety Study of Trivalent Cell Culture Seasonal Influenza Vaccination (TIVc) (Optaflu) among Adults in Routine UK Care

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Influenza vaccine (Optaflu) (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Nov 2017 New trial record
    • 20 Nov 2017 According to results published in the Pharmacoepidemiology and Drug Safety Journal, this study was stopped when just over half of the planned number of exposures had been identified because the product marketing was discontinued.
    • 20 Nov 2017 Results published in the Pharmacoepidemiology and Drug Safety Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top